| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Protalix Biotherapeutics, Inc. (PLX) has 9 insiders with recent SEC Form 4 filings, including 3 buys and 0 sells. PLX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 225.8K | $487.8K | - | |
| CEO | 188.5K | $407.2K | - | |
| Dir | 7.5K | $16.2K | - | |
| Dir | 7.5K | $16.2K | - | |
| Dir | 7.5K | $16.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2015 | Maimon Yossi | Vice President &CFO | Buy | 10,000 | $0.78 | $7,800.00 | New | |
| Oct 19, 2015 | Camber Capital Management LLC | 10% Owner | Buy | 4,000,423 | $1.00 | $4,000,435.69 | +17.7% |